TAK-020   Click here for help

GtoPdb Ligand ID: 11730

Synonyms: compound 3 [PMID: 34448571] | TAK020
PDB Ligand
Compound class: Synthetic organic
Comment: TAK-020 is a covalent Bruton's tyrosine kinase (BTK) inhibitor [2]. The compound bonds to Cys481 in BTK's ATP binding site. It was designed for potential to treat haematologic malignancies and/or autoimmune diseases.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 2
Rotatable bonds 5
Topological polar surface area 103.97
Molecular weight 351.13
XLogP 2.65
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C=CC(=O)N1CC[C@@H](C1)Oc1nc(cc2c1cccc2)c1n[nH]c(=O)[nH]1
Isomeric SMILES C(=O)(C=C)N1C[C@H](CC1)Oc1nc(cc2ccccc12)c1[nH]c(=O)[nH]n1
InChI InChI=1S/C18H17N5O3/c1-2-15(24)23-8-7-12(10-23)26-17-13-6-4-3-5-11(13)9-14(19-17)16-20-18(25)22-21-16/h2-6,9,12H,1,7-8,10H2,(H2,20,21,22,25)/t12-/m0/s1
InChI Key HIMUHMBGRATXMK-LBPRGKRZSA-N
References
1. Esfandiari E, Chen M, Smithson G, Blair D, Faessel H, Wagner J, Mclean L, Fedyk ER. (2021)
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single-Dose and Multiple-Rising-Dose Study of the BTK Inhibitor TAK-020 in Healthy Subjects.
Clin Transl Sci, 14 (3): 820-828. [PMID:33650758]
2. Sabat M, Dougan DR, Knight B, Lawson JD, Scorah N, Smith CR, Taylor ER, Vu P, Wyrick C, Wang H et al.. (2021)
Discovery of the Bruton's Tyrosine Kinase Inhibitor Clinical Candidate TAK-020 (S)-5-(1-((1-Acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-2,4-dihydro-3H-1,2,4-triazol-3-one, by Fragment-Based Drug Design.
J Med Chem, 64 (17): 12893-12902. [PMID:34448571]